Rocket Doctor AI

Rocket Doctor AI P/B

Delisted

The P/B (Price-to-Book Ratio) of Rocket Doctor AI (TRUE.CN) as of Nov 16, 2026 is 88.65. In the previous year, P/B (Price-to-Book Ratio) was -95.22 — a change of -193.10% (higher).

P/B

88.65

YoY

-193.10%

Last updated:

P/B (Price-to-Book Ratio) of Rocket Doctor AI is 2024 88.65 . P/B (Price-to-Book Ratio) of Rocket Doctor AI was 2023 -95.22 . It decreases by -193.10% higher compared to the previous year.

The Rocket Doctor AI P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2017
-1,909.78 CAD
Jan 1, 2018
7,028.00 CAD
Jan 1, 2019
200.74 CAD
Jan 1, 2020
-266.92 CAD
Jan 1, 2021
639.49 CAD
Jan 1, 2022
-32.11 CAD
Jan 1, 2023
-95.22 CAD
Jan 1, 2024
88.65 CAD
The Rocket Doctor AI P/B history
YEARP/BYoY
88.65-193.10%
-95.22+196.52%
-32.11-105.02%
639.49-339.58%
-266.92-232.97%
200.74-97.14%
7,028.00-468.00%
-1,909.78—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rocket Doctor AI Stock analysis

What does Rocket Doctor AI do? Treatment.com AI Inc generates revenue through its Treatment Digital Health App, a symptom assessment tool developed by a global team of doctors and engineers. The app provides predictive health insights using disease rate estimates, geographic variation data, and medical research, targeting patients and caregivers seeking informed health decisions. The company also offers medical education solutions and clinical advisor services, serving healthcare professionals and institutions globally. Revenue streams include subscriptions for app access and tailored medical education programs. The Treatment Digital Health App is designed for widespread use, offering advanced medical knowledge access to users worldwide. Medical clinic solutions are integrated into the platform, supporting healthcare providers in decision-making. Clinical advisor services leverage the AI platform to assist clinics and institutions with specialized medical guidance. These offerings are marketed to healthcare consumers, clinics, and educational institutions as part of the company's global healthcare technology strategy. Treatment.com AI Inc's business model focuses on AI-driven health solutions, with the Treatment Digital Health App as its primary product. The app's predictive health assessments are updated regularly by medical professionals, ensuring relevance and accuracy. The company monetizes through direct consumer subscriptions and B2B partnerships with medical clinics and educational providers, emphasizing global accessibility and evidence-based medical insights. Rocket Doctor AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rocket Doctor AI stock

P/B (Price-to-Book Ratio) of Rocket Doctor AI is 88.65 in 2024.

P/B (Price-to-Book Ratio) of Rocket Doctor AI changed from -95.22 to 88.65, representing a -193.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Rocket Doctor AI since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Rocket Doctor AI with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Rocket Doctor AI

All Key Metrics — Rocket Doctor AI